Precision Antibiotic Improves Outcome of Gut Infections in Phase II
Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more…
The potential of the microbiome to be used for the development of promising therapeutics and diagnostic approaches has spurred a hype around this emerging field. Over the last decade, researchers have found correlations between the human microbiome and a number of diseases, including inflammatory bowel disease, diabetes, autoimmune diseases, cancer, depression, and many more. As the number of clinical trials grows, investor interest is increasing.
Read on to find out more about the flourishing microbiome field and how it shows promise for the treatment of a large variety of diseases.
Beyond the Gut: An Atlas of the Human Microbiome
This report discusses the role of the gut and blood microbiomes in different diseases and how they can be used for biomarker discovery and for the development of therapeutics.
Go to ReportSummit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more…
With the rise of antimicrobial resistance across the globe, and with a dire lack of…
Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical…
UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s…
The human microbiome is emerging as a target for treating a wide range of diseases,…
MaaT Pharma, based in Lyon, has received authorization to launch a Phase II trial for…
Valbiotis has shown that its treatment restores diversity in a population of gut microorganisms imbalanced…
Micropia, a museum of microbes located in the heart of Amsterdam, uses art to address the big…
Enterome will use the money to progress two of its leading microbiome programs for the…
BiomX has acquired RondinX, expanding its bacterial target discovery platform and adding new microbiome targets…
Biomillenia harnesses the power of bacteria to keep the body healthy. The biotech has joined…
LNC Therapeutics is ready to take its oral microbiome-based therapeutic to market for obesity. Investors…